Symbol="INKT"
AssetType="Common Stock"
Name="Mink Therapeutics Inc"
Description="MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic, ready-to-use, invariant natural killer T-cell therapies for treating cancer and other immune-mediated diseases. The company is headquartered in New York, New York."
CIK="1840229"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="149 FIFTH AVENUE, SUITE 500, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="62304000"
EBITDA="-29288728"
PERatio="None"
PEGRatio="None"
BookValue="-0.13"
DividendPerShare="0"
DividendYield="0"
EPS="-0.77"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.698"
ReturnOnEquityTTM="-4.037"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.77"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="8.33"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="11.5"
EVToRevenue="-"
EVToEBITDA="-3.702"
Beta="None"
num_52WeekHigh="4.32"
num_52WeekLow="0.851"
num_50DayMovingAverage="2.047"
num_200DayMovingAverage="2.14"
SharesOutstanding="34422100"
DividendDate="None"
ExDividendDate="None"
symbol="INKT"
open="1.74"
high="1.85"
low="1.70"
price="1.81"
volume="58316.00"
latest_trading_day="2023-08-04"
previous_close="1.72"
change="0.09"
change_percent="5.2326%"
aroon_positive_momentum_days="51"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="51"
Volume_recent_avg="135915"
Change_recent_avg="-0.03"
Delta_recent_avg="0.22"
Variance_recent_avg="0.11"
Change_ratio_recent_avg="-1.81"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="51"
Aroon_momentum_negative="49"
image_negative_thumbnail_id_1="1111"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0144.jpeg"
image_negative_thumbnail_id_2="1128"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0161.jpeg"
image_neutral_thumbnail_id_1="547"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0052.jpeg"
image_neutral_thumbnail_id_2="555"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0044.jpeg"
image_positive_thumbnail_id_1="680"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0028.jpeg"
image_positive_thumbnail_id_2="992"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0154.jpeg"
image_professor_thumbnail_id_1="1203"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0037.jpeg"
image_professor_thumbnail_id_2="1177"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0011.jpeg"
